Newtyn Management LLC Acquires 2,066,528 Shares of QuidelOrtho Corporation $QDEL

Newtyn Management LLC boosted its holdings in QuidelOrtho Corporation (NASDAQ:QDEL) by 45.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,625,000 shares of the company’s stock after acquiring an additional 2,066,528 shares during the quarter. QuidelOrtho accounts for approximately 14.7% of Newtyn Management LLC’s investment portfolio, making the stock its biggest holding. Newtyn Management LLC owned 0.10% of QuidelOrtho worth $116,037,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in QDEL. Global Retirement Partners LLC raised its stake in shares of QuidelOrtho by 3,691.7% in the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock worth $26,000 after purchasing an additional 886 shares during the last quarter. Hantz Financial Services Inc. grew its holdings in QuidelOrtho by 50.3% during the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock worth $31,000 after buying an additional 362 shares in the last quarter. GAMMA Investing LLC grew its holdings in QuidelOrtho by 67.7% during the second quarter. GAMMA Investing LLC now owns 2,185 shares of the company’s stock worth $38,000 after buying an additional 882 shares in the last quarter. Larson Financial Group LLC raised its position in QuidelOrtho by 322.2% in the 3rd quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after buying an additional 1,015 shares during the last quarter. Finally, Allworth Financial LP bought a new position in QuidelOrtho during the 2nd quarter valued at $56,000. 99.00% of the stock is owned by institutional investors.

QuidelOrtho Stock Performance

NASDAQ:QDEL opened at $14.74 on Monday. The company has a market capitalization of $1.01 billion, a P/E ratio of -0.96 and a beta of 0.68. The business has a fifty day simple moving average of $15.93 and a two-hundred day simple moving average of $15.94. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.39 and a quick ratio of 0.76. QuidelOrtho Corporation has a 1 year low of $9.92 and a 1 year high of $35.58.

QuidelOrtho (NASDAQ:QDEL) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.18. The firm had revenue of $630.90 million for the quarter, compared to analysts’ expectations of $618.72 million. QuidelOrtho had a positive return on equity of 4.88% and a negative net margin of 39.20%.The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.12 EPS. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. On average, analysts expect that QuidelOrtho Corporation will post 0.75 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Zacks Research downgraded shares of QuidelOrtho from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of QuidelOrtho in a report on Friday, July 17th. UBS Group reissued a “neutral” rating and set a $12.00 price target on shares of QuidelOrtho in a research report on Thursday, May 7th. Wall Street Zen upgraded shares of QuidelOrtho from a “sell” rating to a “hold” rating in a report on Sunday, June 28th. Finally, Citigroup upped their price objective on shares of QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Three equities research analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, QuidelOrtho presently has an average rating of “Reduce” and a consensus price target of $13.62.

QuidelOrtho Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.